Suppr超能文献

干扰素α与利巴韦林联合抗病毒治疗对伴有肝外表现的慢性丙型肝炎患者的疗效

[Efficacy of combined antiviral therapy with interferon alfa and ribavirin in chronic hepatitis C patients with extrahepatic manifestations].

作者信息

Zarebska-Michaluk Dorota, Lebensztejn Dariusz Marek, Kryczka Wiesław

机构信息

Oddział Obserwacyjno-Zakaźny, Wojewódzki Szpital Zespolony w Kielcach.

出版信息

Przegl Epidemiol. 2007;61(3):551-8.

Abstract

The aim of the study was to assess the efficacy and safety of treatment with interferon alpha and ribavirin in patients with chronic hepatitis C and extrahepatic manifestations as well as to determine prognostic factors of therapy effectiveness. 179 consecutive naive patients with chronic hepatitis C treated with interferon alpha and ribavirin were studied. 120 patients (67%) presented extrahepatic manifestations. The most frequent were cryoglobulinaemia, thrombocytopenia and thyroid gland pathology. Efficacy of antiviral treatment was lower (SVR 33.3% vs. 52.5%, p=0.013) and frequency of adverse events higher in patients with chronic hepatitis C and extrahepatic manifestations in comparison to those without extrahepatic pathology. Younger age, shorter duration of HCV infection and less advanced liver fibrosis were prognostic factors of better response to antiviral therapy in group of patients with chronic hepatitis C and extrahepatic manifestations.

摘要

本研究的目的是评估α干扰素和利巴韦林治疗慢性丙型肝炎合并肝外表现患者的疗效和安全性,并确定治疗有效性的预后因素。对179例连续接受α干扰素和利巴韦林治疗的初治慢性丙型肝炎患者进行了研究。120例患者(67%)出现肝外表现。最常见的是冷球蛋白血症、血小板减少和甲状腺疾病。与无肝外病变的患者相比,慢性丙型肝炎合并肝外表现患者的抗病毒治疗疗效较低(持续病毒学应答率为33.3% vs. 52.5%,p = 0.013),不良事件发生率较高。在慢性丙型肝炎合并肝外表现的患者组中,年龄较小、HCV感染持续时间较短和肝纤维化程度较轻是对抗病毒治疗反应较好的预后因素。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验